TransMedics Group Inc. (TMDX) Insider Trading

Last 12 months

Insiders bought $1.11M and sold $4.87M on the open market.

11% of the selling was scheduled in advance under 10b5-1 plans. Chief Financial Officer Gerardo Hernandez sold $1.12M on Mar 4, 34% of their stake, outside a plan.

Net open-market

−$3.76M

2 buys · 10 sales

Under a 10b5-1 plan

11%

of the value sold

Insiders who bought / sold

2 / 7

executives and directors

Last open-market buy

Sep 2026

Sep 11, 2026

Get an email when TMDX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 11	David Weill Director	Bought	1,336	$81.63	$109k	8.9%	Form 4
Jun 15	Thomas J. Gunderson Director	SoldNo plan	9,624	$75.06	$722k	37%	Form 4
Mar 4	Stephanie Lovell Director	SoldNo plan	1,193	$149.62	$178k	29%	Form 4
Mar 4	David Weill Director	SoldNo plan	3,571	$146.82	$524k	23%	Form 4
Mar 2 – 4	Gerardo Hernandez Chief Financial Officer	SoldNo plan 3 parts	7,611	$146.81 average	$1.12M	34%	Form 4
Mar 2	Anil P. Ranganath See remarks	SoldNo plan	864	$139.12	$120k	6.2%	Form 4
Mar 2	Nicholas Corcoran See remarks	SoldNo plan	2,966	$139.12	$413k	9.0%	Form 4
Dec 4, 2025	Gerardo Hernandez Chief Financial Officer	SoldNo plan	920	$139.62	$128k	5.8%	Form 4
Dec 3, 2025	David Weill Director	SoldNo plan	5,000	$138.64	$693k	29%	Form 4
Nov 25, 2025	Anil P. Ranganath See remarks	SoldNo plan	3,000	$145.22	$436k	18%	Form 4
Nov 17, 2025	Waleed H Hassanein President & CEO	Bought	8,775	$114.00	$1M	1.4%	Form 4
Oct 29, 2025	Edward M Basile Director	Sold10b5-1 plan	4,142	$130.45	$540k	59%	Form 4
Aug 6, 2025 – Aug 7, 2025	Waleed H Hassanein President & CEO	Bought 3 parts	16,875	$117.46 average	$1.98M	2.9%	Form 4
Aug 4, 2025	Edward M Basile Director	Sold10b5-1 plan	4,143	$125.51	$520k	59%	Form 4
Jun 9, 2025	Anil P. Ranganath See remarks	SoldNo plan	686	$139.80	$96k	4.7%	Form 4
May 27, 2025	Edward M Basile Director	Sold10b5-1 plan	5,000	$126.45	$632k	64%	Form 4
May 23, 2025	David Weill Director	SoldNo plan	732	$123.88	$91k	5.7%	Form 4
May 9, 2025	Edward M Basile Director	Sold10b5-1 plan	6,000	$115.63	$694k	89%	Form 4
Mar 3, 2025	Tamer I Khayal Chief Commercial Officer	SoldNo plan	2,407	$76.43	$184k	6.3%	Form 4
Jan 7, 2025	Tamer I Khayal Chief Commercial Officer	Sold10b5-1 plan	1,083	$80.05	$87k	4.9%	Form 4
Dec 2, 2024	Tamer I Khayal Chief Commercial Officer	Sold10b5-1 plan	1,084	$86.40	$94k	4.9%	Form 4
Nov 11, 2024	Tamer I Khayal Chief Commercial Officer	Sold10b5-1 plan	1,458	$90.04	$131k	6.5%	Form 4
Nov 5, 2024	Edward M Basile Director	Sold10b5-1 plan 2 parts	6,750	$83.55 average	$564k	90%	Form 4
Nov 1, 2024	Tamer I Khayal Chief Commercial Officer	Sold10b5-1 plan	1,083	$82.64	$89k	4.9%	Form 4

Sep 11
David Weill
Director · bought 1,336 at $81.63
$109k
8.9% of stake
Jun 15No plan
Thomas J. Gunderson
Director · sold 9,624 at $75.06
$722k
37% of stake
Mar 4No plan
Stephanie Lovell
Director · sold 1,193 at $149.62
$178k
29% of stake
Mar 4No plan
David Weill
Director · sold 3,571 at $146.82
$524k
23% of stake
Mar 2 – 4No plan
Gerardo Hernandez
Chief Financial Officer · sold 7,611 at avg $146.81
$1.12M
34% of stake
Mar 2No plan
Anil P. Ranganath
See remarks · sold 864 at $139.12
$120k
6.2% of stake
Mar 2No plan
Nicholas Corcoran
See remarks · sold 2,966 at $139.12
$413k
9.0% of stake
Dec 4, 2025No plan
Gerardo Hernandez
Chief Financial Officer · sold 920 at $139.62
$128k
5.8% of stake
Dec 3, 2025No plan
David Weill
Director · sold 5,000 at $138.64
$693k
29% of stake
Nov 25, 2025No plan
Anil P. Ranganath
See remarks · sold 3,000 at $145.22
$436k
18% of stake
Nov 17, 2025
Waleed H Hassanein
President & CEO · bought 8,775 at $114.00
$1M
1.4% of stake
Oct 29, 202510b5-1 plan
Edward M Basile
Director · sold 4,142 at $130.45
$540k
59% of stake
Aug 6, 2025 – Aug 7, 2025
Waleed H Hassanein
President & CEO · bought 16,875 at avg $117.46
$1.98M
2.9% of stake
Aug 4, 202510b5-1 plan
Edward M Basile
Director · sold 4,143 at $125.51
$520k
59% of stake
Jun 9, 2025No plan
Anil P. Ranganath
See remarks · sold 686 at $139.80
$96k
4.7% of stake
May 27, 202510b5-1 plan
Edward M Basile
Director · sold 5,000 at $126.45
$632k
64% of stake
May 23, 2025No plan
David Weill
Director · sold 732 at $123.88
$91k
5.7% of stake
May 9, 202510b5-1 plan
Edward M Basile
Director · sold 6,000 at $115.63
$694k
89% of stake
Mar 3, 2025No plan
Tamer I Khayal
Chief Commercial Officer · sold 2,407 at $76.43
$184k
6.3% of stake
Jan 7, 202510b5-1 plan
Tamer I Khayal
Chief Commercial Officer · sold 1,083 at $80.05
$87k
4.9% of stake
Dec 2, 202410b5-1 plan
Tamer I Khayal
Chief Commercial Officer · sold 1,084 at $86.40
$94k
4.9% of stake
Nov 11, 202410b5-1 plan
Tamer I Khayal
Chief Commercial Officer · sold 1,458 at $90.04
$131k
6.5% of stake
Nov 5, 202410b5-1 plan
Edward M Basile
Director · sold 6,750 at avg $83.55
$564k
90% of stake
Nov 1, 202410b5-1 plan
Tamer I Khayal
Chief Commercial Officer · sold 1,083 at $82.64
$89k
4.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TMDX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Electromedical & Electrotherapeutic Apparatus

INMDInMode Ltd.

AXGNAxogen Inc.

OMOutset Medical Inc.

ZYXIQZynex Inc

FONRFonar Corp

BLFSBiolife Solutions Inc.

CBLLCeribell, Inc.

VASOVaso Corporation

Spot a number that looks wrong? Check it in TMDX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TMDX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.